Medunik Canada, a Canadian pharmaceutical company specialized in orphan drugs, is pleased to announce that Health Canada has issued a Notice of Compliance (NOC) for Pheburane (a tasteless oral formulation of sodium phenylbutyrate), indicated as adjunctive therapy in the chronic management of urea cycle disorders (UCD), involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase. Canadians living with a urea cycle disorder will now have access to an approved tasteless medication for the treatment of this metabolic disease.

"We worked very hard to develop a tasteless oral formulation of sodium phenylbutyrate and we are pleased to see that Medunik has succeeded in making Pheburane accessible to Canadians in need of this treatment option." said Pierre Mambrini, CEO of Lucane Pharma.

"UCDs are part of the rare disease family and today, I am proud and excited that the few Canadians looking to improve the management of their chronic condition have now access to Pheburane. We are convinced that this will provide patients and their family with a real benefit." said Éric Gervais, Executive Vice-President of Medunik Canada.

For more details, go to: http://www.medunikcanada.com/en/news-and-press-releases/press-releases/medunik-canada-is-pleased-to-announce-that-health-canada-has-granted-market-authorization-for-pheburane